Celgene's pomalidomide and Aegerion's Lojuxta in latest CHMP nods
This article was originally published in Scrip
Executive Summary
The EU's CHMP granted positive opinions on approval of seven new medicines at its latest meeting on 27-30 May. They included Celgene's multiple myeloma treatment pomalidomide, and Aegerion's novel hyperlipidemia therapy lomitapide.